I don't know if we can say select shareholders. It could just be what is asked and when it is asked. It would seem that the plan is to release the financials this quarter. So we will see if that happens.
Arrayit Corporation CEO Letter to Shareholders
Sunnyvale, CA - December 31, 2018
Dear ARYC Shareholders,
Arrayit Corporation, its Board of Directors and CEO would like to express sincere
appreciation to all shareholders who made the decision to invest in ARYC. As previously
announced via Arrayit’s newsletter, press releases and social media during 2018, the
company achieved major milestones, including 25 years in business. Arrayit established a
nationwide network of 1,700 allergy sales professionals, signed allergy testing contracts
with more than 300 medical clinics, launched the Patient Data Solutions allergy portal for
doctors and clinics, and fulfilled a clinical instrumentation contract with the FDA after a
face-to-face regulatory meeting, among others. We continue to pursue completion of a
multi-year audit to bring ARYC’s public company financial reporting current. The CEO,
Board of Directors and our dedicated team of employees, advisors and consultants have
created a vibrant, new Arrayit Corporation that is primed for intensive growth as a high
volume clinical laboratory.
During the second half of 2018, Arrayit expanded its shareholder base, completed
multiple VIP shareholder tours, issued bi-weekly press releases and provided more than
1,000 real-time daily shareholder updates via Twitter. We completed a meeting with top
officials at the FDA regarding a major product line and received substantial feedback. In
our dynamic business-to-business relationship with Pinner USA, we received Pinnertest
dietary wellness test endorsement from dozens of celebrity athletes, entertainers,
musicians, actors, chefs, authors, bloggers, and health and wellness lifestyle experts. At
year end, we implemented a new electronic medical billing solution and we expect to bill
$1 million per week for our health and wellness tests. The actual contribution of medical
reimbursement to our revenues and earnings will be detailed in financial reports, which
we anticipate filing in the coming quarter.
For 2019, Arrayit Corporation sets some ambitious goals, most particularly for finger-
stick allergy and lifestyle wellness testing. We will continue regular proficiency testing as
we pursue additional laboratory accreditation for even greater access to reimbursement.
We will continue to add hundreds of new clinics and doctors to the Patient Data Solutions
portal. We will extend promotions with top retailers and add allergy sales professionals.
We will solidify reference laboratory relationships with various government agencies. We
will explore expansion into testing markets abroad. We will make new hires and refine
our future business and financial objectives, including potential up listing.
